fxia

FXIa is a pre-hemoglobin variant of the hemoglobin molecule, specifically a variant of the alpha-globin chain. It is one of the several pathogenic hemoglobin variants discovered in the alpha-globin chain. FXIa results from a mutation in the HBA1 gene, which codes for the alpha-gene.

Individuals with FXIa typically exhibit microcytic hypochromic anemia, characterized by small red blood cells that contain reduced amounts of hemoglobin. This condition can manifest either as an isolated anomaly in an offspring or as a component of the hemoglobinopathy known as alpha-thalassemia. The latter is even more likely if the FXIa mutation is combined with alpha-thalassemia.

The pathogenicity of FXIa is primarily determined by the polymerization of the mutant subunits, leading to their rapid degradation and reduced availability for binding with beta-globin chains to produce hemoglobin. Research into the structural and functional anomalies of FXIa provides insights into the mechanisms by which certain mutations lead to severe hemoglobinopathy. The interactions between the alpha- and beta-gene mutations are essential to clarify the nature of globinopathies and the therapeutic implications for clinical treatments.

Studies on FXIa emphasize the importance of identifying the correct pathogenic signatures of this molecule in the context of alpha-gene diversity. Further investigation is required to better elucidate the physiological consequences of the FXIa mutation in the broader framework of hemoglobinopathies and by extension, to carry out its heuristic impact on genetics, molecular biology, and medicine.